the aid library

LIST OPTIONS

Filter

4835

Criterios de diagnóstico y tratamiento de la tuberculosis infantil

Gonzales N., et al. (2022) CC

El agente etiológico de la tuberculosis es el Mycobacterium tuberculosis o bacilo de Koch. Se trata de un bacilo aerobio estricto, ácido-alcohol resistente, sin movilidad, de crecimiento lento y que se inactiva con rayos ultravioleta y temperaturas mayores de 60°C.

Download (481)

View PDF (884)

Nepal: 2011 Demographic and Health Survey Key Findings

Ministry of Health and Population, USAID (2012) C1

Download (844)

View PDF (1007)

Management of Alcohol Dependence. Background Document

National Health Mission; Ministry of Health & Social Welfare India (2016) C1

Standard Treatment Guideline

External Link

The impact of training on self-reported performance in reproductive, maternal, and newborn health service delivery among healthcare workers in Tanzania: a baseline- and endline-survey

Tumbwene, M.; Mbekenga, C.; Isangula, K.; et al. (2022) CC2

Reprod Health 19, 143 (2022). https://doi.org/10.1186/s12978-022-01452-4. Delivery of quality reproductive health services has been documented to depend on the availability of healthcare workers who are adequately supported with appropriate training. However, unmet training needs among healthcare ... more

Download (198)

View PDF (260)

Interim Briefing Note - Addressing Mental Health and Psychosocial Aspects of COVID-19 Outbreak - Version 1.5

IASC Reference Group on Mental Health and Psychosocial Support in Emergency Settings; OCHA Services (2020) C2

February 2020

Download (153)

View PDF (106)

Health Financing Progress Matrix assessment, Kenya 2023: summary of findings and recommendations

Kenya Ministry of Health, World Health Organization (WHO) (2024) CC

This comprehensive HPFM report thoroughly explores Kenya’s health financing landscape. It provides an in-depth analysis of the current state of affairs and sheds light on required strategic changes in health financing. The report points out the need to improve public financial management within th... more

Download (27)

View PDF (22)

Violence Against Children and Youth in Namibia

Ministry of Gender Equality, Poverty Eradication and Social Namibia (2020) CC2

Namibia has, for many years, had a strong legislative and policy framework for the protection of children. These policies and laws have been developed through the combined expertise of those working in the field of child protection who have ensured Namibia has a robust legal framework that is in li... more

Download (266)

View PDF (258)

Movilidad poblacional y VIH/sida en Centroamérica y México

R. Leyva-Flores; B. Aracena-Genao; E. Serván-Mori PAHO (Pan American Health Organization; World Health Organization); Rev Panam Salud Publica; Pan American Journal of Public Health (2014) C2

Investigación original / Original research Rev Panam Salud Publica 36(3), 2014

Download (278)

View PDF (414)

Faith Sector Key HIV Messages for Mainstreaming

Ministry of Health, Kenya; National AIDS Control Council (2018) C1

The National AIDS Control Council recognizes the growing, organized and progressive inter-faith religious voice in the spheres of governance and development in Kenya. Across the country, the Faith Sector has been involved in HIV prevention, treatment, care and support to programmes towards... more

Download (157)

View PDF (113)

Trichiasis surgery for trachoma
recommended

World Health Organization WHO (2024) C_WHO

3rd edition

Download (34)

View PDF (25)

Technical consultation to assess evidence on community-based delivery of intermittent preventive treatment in pregnancy for malaria

World Health Organization WHO (2023) C_WHO

Report of a virtual meeting 21–23 June 2022

Download (757)

View PDF (1300)

National Blood Policy

NACO, NBTC (2007)

Download (475)

View PDF (702)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (1561)

View PDF (3311)

Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025

World Health Organization; UNICEF (2013) C_WHO

The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)

Trichiasis surgery for trachoma recommended

Trichiasis surgery for trachoma
recommended